Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Frontotemporal dementia (FTD) is a significant cause of dementia, particularly in younger individuals.
• Current understanding of FTD pathophysiology suggests potential therapeutic targets in serotonergic and dopaminergic systems.
• There is a lack of large-scale treatment trials and standardized protocols for FTD research.

Purpose of the Study:

• To review existing literature on therapeutic trials for FTD.
• To outline recommendations for establishing standards in future FTD treatment studies.
• To identify drugs tested and their reported efficacy and adverse effects in FTD.

Main Methods:

• Literature review of published therapeutic trials in FTD.
• Analysis of drugs tested, including antidepressants, stimulants, and other agents.
• Examination of study designs, including double-blind placebo-controlled trials.

Main Results:

• Numerous drugs have been tested in FTD, with reported improvements for most, except piracetam, guanfacine, and galantamine (though galantamine showed benefit in primary progressive aphasia).
• Selective serotonin reuptake inhibitors (SSRIs), idazoxan, and methylphenidate showed mixed results, with some reports of functional decline.
• Calcium EDTA showed improvement in patients with Pick's disease, a subtype of FTD.

Conclusions:

• The efficacy of various drugs in FTD is inconsistent, and some treatments may lead to functional decline.
• There is a critical need for consensus among FTD experts to establish standardized criteria for diagnostic, severity, design, and outcome measures in clinical trials.
• Standardization will facilitate robust comparisons across studies and accelerate the development of effective FTD therapies.